PR Newswire PharmaOriginal article
Terapia de edición bases con tBE logra remisión clínica duradera en drepanocitosis y β-talasemia en varios fondos genét
Data ReadoutpositivetBEPositive
AI Analysis
Summary
Base editing therapy (tBE) achieved durable clinical remission in sickle cell disease and β-thalassemia patients across different genetic backgrounds, with demonstrated transfusion independence in Chinese thalassemia patients, according to Cell Stem Cell publication.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Base editing therapy (tBE) achieved durable clinical remission in sickle cell disease and β-thalassemia across different genetic contexts, with transfusion independence achieved in Chinese patients with thalassemia
Importance:7/10
Sentiment:
0.85
base editinggene therapysickle cell diseasebeta-thalassemiaclinical remissiontransfusion independence
Read the original article
Published by PR Newswire Pharma on September 9, 2026 9:00 AM